Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376994 · ClinicalTrials.gov registry record · Phase 3
Multi-Center Clean Air Randomized Controlled Trial in COPD
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by JHSPH Center for Clinical Trials.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
- 11
- Study locations
NCT06376994: Recruiting Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by JHSPH Center for Clinical Trials.
NCT06376994 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by JHSPH Center for Clinical Trials. The registered enrollment target is 770 participants, above the 630-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (22% higher). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06376994, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by JHSPH Center for Clinical Trials.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.
Primary Outcome
The St. George's Respiratory Questionnaire (SGRQ) is a widely used measure of disease impact as an indicator of disease-specific quality of life. The SGRQ is a disease specific instrument containing 50 items in three subscales (symptoms, activity, and impact). Scores range from 0 to 100, with higher scores indicating more limitations.
Conditions Studied
Interventions
- DEVICE Air cleaner
- DEVICE Sham air cleaner
Study Locations (11)
Maryland
- University of Maryland - Baltimore
- Johns Hopkins - Baltimore
- Tidal Health - Salisbury
Alabama
- University of Alabama, Lung Health Center - Birmingham
California
- University of California, Los Angeles - Los Angeles
Iowa
- University of Iowa - Iowa City
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
New Hampshire
- Dartmouth Hitchcock - Lebanon
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 3 |
What NCT06376994 shows while recruiting
NCT06376994 is an interventional study that assigns participants to a tested intervention. The registered 770 participants enrollment target is mid-sized for trials with a published cap, above the 630-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Air cleaner is the first listed.
NCT06376994 lists 11 locations in 9 states (Maryland, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT06376994 about?
NCT06376994 is a clinical study titled "Multi-Center Clean Air Randomized Controlled Trial in COPD". This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.
What is the current status of trial NCT06376994?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2024-05-24. Estimated completion is 2029-11-30.
What conditions does trial NCT06376994 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT06376994?
The interventions under investigation include: Air cleaner (DEVICE), Sham air cleaner (DEVICE).
Who is sponsoring clinical trial NCT06376994?
This trial is sponsored by JHSPH Center for Clinical Trials, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376994 being conducted?
This trial has 11 study locations across Alabama, California, Iowa, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06376994's enrollment target sits among peer trials
770 16th of 36 higher than 21 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977348 · 770 participants · NA
Increasing Food Literacy in Preschoolers to Reduce Obesity Risk
- NCT06824467 · 770 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- NCT06907173 · 770 participants · Phase 3
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
- NCT07209254 · 770 participants · NA
Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI